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Abstract This report presents the historical experience,
clinical presentation, treatment, prognosis, and pathogene-
sis of gliosarcoma described to date in the English literature.
PubMed query of term ‘‘gliosarcoma’’ was performed, fol-
lowed by a rigorous review of cited literature. Articles
selected for analysis included: (1) case reports of gliosar-
coma, (2) review articles of gliosarcoma, and (3) studies of
the pathogenesis or genetics of gliosarcoma in humans. Our
review identified 219 cases of gliosarcoma in 34 reports and
eight articles addressing the pathogenesis. Survival in larger
series ranged 4–11.5 months. Features unique to gliosar-
coma compared to glioblastoma (GBM) include their tem-
poral lobe predilection, potential to appear similar to a
meningioma at surgery, repeated reports of extracranial
metastases, and infrequency of EGFR mutations. Pub-
lished experience is limited to small case series, and the
pathogenesis remains unclear. Clinical and pathologic
characteristics distinct from GBM suggest that they may
warrant specific treatment, separate from conventional
GBM therapy.
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Introduction
Gliosarcoma was initially described by Stroebe in 1895 as
a brain neoplasm consisting of both glial and mesenchymal
components [1]. This biphasic tumor subsequently gained
general acceptance from detailed histological analyses of
Feigen and colleagues [2, 3]. Due to lack of specific and
uniform diagnostic criteria however, the term gliosarcoma
was also applied to tumors of glial origin that have taken on
mesenchymal phenotypes, such as the ability to produce
reticulin and collagen [2]. Over time, these tumors were
understood as distinct entities, one being a tumor of glial
origin taking on mesenchymal characteristics, termed
desmoplastic glioma or glioma with desmoplastic meta-
plasia, the other entity being a tumor with distinct glio-
matous and sarcomatous components, termed gliosarcoma
[4]. The 2007 World Health Organization classification
scheme places primary gliosarcoma (PGS) as a grade IV
neoplasm and a variant of glioblastoma multiforme (GBM)
[5]. The current accepted definition of PGS is a well-cir-
cumscribed lesion with clearly identifiable biphasic glial
and metaplastic mesenchymal components [6]. Histologi-
cally, the glial component fulfills the cytologic criteria of
GBM, and the mesenchymal component may show a wide
variety of morphologies with origins from fibroblastic,
cartilaginous, osseous, smooth and striated muscle, or adi-
pose cell lineage. The current definition, however, lacks
pathologic consensus, particularly regarding the relative
predominance of a single element. As clinical and patho-
logic features of PGS continue to be elucidated, more
rigorous diagnostic criteria must be considered. The current
classification of PGS as a variant of GBM reflects the fact
that they are often treated in the same manner; however
anecdotal evidence suggests that PGS are distinct from
GBM. In this report we review the published English
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language literature to highlight the unique clinical and
pathologic features of PGS (Figs. 1, 2, 3).
Methods
Articles were identified through a PubMed query using the
keyword ‘‘gliosarcoma’’. The cited references of the sour-
ces were also searched. 757 citations reported to date were
screened using our inclusion criteria. Articles selected for
analysis included: (1) case reports or series of gliosarcoma
patients, (2) review articles of gliosarcoma, or (3) experi-
ments studying the pathogenesis or genetics of gliosarcoma
in humans. The search yielded 34 case series and reports
meeting our criteria and included a total of 219 cases of
PGS. Majority of these published series included cases of
gliosarcoma based on the WHO criteria for gliosarcoma.
Pathogenesis
The pathogenesis of gliosarcoma has been a topic of con-
troversy and currently remains unknown. In addition, there
has been no detailed study to date that focuses on genetic
and pathologic differences between PGS and secondary
gliosarcoma. Early reports suggested that the sarcomatous
components originated from neoplastic transformation of
hyperplastic blood vessels commonly found in high grade
gliomas [2]. This ‘‘collision tumor’’ concept was supported
by early descriptions by Feigin of hyperplastic vessels and
perivascular arrangement of sarcomatous elements in gli-
osarcoma [7]. Studies showing histological reactivity of the
sarcomatous component to vascular endothelial markers
such as factor VIII, von Willebrand factor and CD34 also
provided support for this hypothesis [8–10]. However, a
number of other studies followed that failed to discover the
presence of endothelial markers in the sarcomatous ele-
ments [11–13].
An alternative theory that has recently gained favor points
to a monoclonal origin of both components of gliosarcoma,
with sarcomatous component originating via aberrant mes-
enchymal differentiation of the malignant glioma. Biernat
and colleagues [14] first demonstrated identical p53 muta-
tions in gliomatous and sarcomatous components. Reis and
colleagues [15] discovered identical PTEN mutations, p53
nuclear accumulation, p16 deletion, and CDK4 amplifica-
tions in both tumor areas. Other authors followed, describing
that both components of gliosarcoma shared common
genetic alterations and chromosomal imbalances of the type
classically described in GBM [16, 17]. These alterations
included gains on chromosomes 7, 9q, 20q, and X, and losses
on chromosomes 10, 9p, and 13q [16, 17]. Studies found,
however, a much lower frequency of EGFR amplification in
gliosarcoma than found in primary GBM. While EGFR is
amplified in up to half of primary GBMs, the rate of ampli-
fication is much lower in gliosarcoma (8% in small series)
[15, 16]. Gliosarcomas were also found to have a fewer
number of chromosomes involved in imbalances, suggesting
Fig. 1 Histology of
gliosarcoma. a 2009.
Immunohistochemical staining
for vascular marker CD31,
demonstrating focal perinuclear
positivity in many of the tumor
cells. Positive staining vascular
endothelium serves as internal
control. b 2009. Focal strong
membranous staining of tumor
cells with CD34 antibody.
Positive staining within vascular
endothelium serves as internal
control. c 2009. Focal weak
cytoplasmic staining with
GFAP antibody in tumor cells.
This suggests a glial origin.
d Hematoxylin and eosin stain,
2009. Vascular endothelial
proliferation and myxoid and
chondromatous area in a
gliosarcoma. The tumor cells
show focal myxoid change and
epithelioid morphology
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a higher level of genomic stability in gliosarcomas [16].
Although, there is currently a paucity of data supporting
these genetic markers to be of prognostic value, detailed
future clinicopathologic studies will continue to elucidate
their role in tumorigenesis, progression, and clinical man-
agement of gliosarcomas.
Clinical characteristics
Gliosarcomas are rare and have an incidence 1.8–2.8% that
of GBMs [18]. Similar to other glial based tumors, PGS
affects adults in the sixth to seventh decade of life, with a
significantly higher proportion found in men than in women
(M:F ratio 1.4–1.8:1) [12, 18]. The presenting signs and
symptoms reported are consistent with those of a rapidly
expanding intracranial tumor, including aphasia, headache,
hemiparesis, seizures, and cognitive decline, depending on
its location. The clinical similarities to GBM have led many
authors to conclude that these tumors are clinically indis-
tinguishable [12, 19]. However, there are a number of
important and distinct features of PGS that suggest that it is
a separate entity.
The striking features of PGS that distinguish it from
GBM include its location and its differential radiographic
and gross appearance. Gliosarcoma is almost never found
Fig. 2 Morphology of gliosarcoma a Smear preparation, hematoxy-
lin and eosin stain, 1009. Portion of the tumor showing sarcomatous,
spindle morphology. Other potential differentiation includes osseous,
vascular, skeletal muscle, and adipose phenotypes. b GFAP, 1009.
The sarcomatous component is GFAP negative c 4009. The basement
membrane is highlighted by Laidlaw Reticulin impregnation in the
sarcomatous component of the tumor. Reticulin shows thick uniform
atypical appearance
Fig. 3 Neuroimaging of a gliosarcoma before surgery. Gadolinium-
enhanced T1-weighted axial images of the patient’s left sided
temporal lobe gliosarcoma
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infratentorially and the majority of the reports describe its
temporal lobe predilection [18, 20, 21] while a few report a
higher incidence in the frontal lobe [12, 22]. The published
experience describes two distinct appearances of PGS
grossly at operation. The early case series by Feigin and
Morantz noted the gross appearance of PGS were often
firm, well-circumscribed masses commonly found at the
periphery in contact with the dura mater, falx cerebri or the
skull [3]. However, the series by Perry and colleagues
reported that most cases of gliosarcoma [12] were diffusely
infiltrating with ill defined margins (exact proportions not
given). In contrast the series by Parekh and colleagues
found only 2 of 15 cases had such characteristics on gross
appearance [12, 21]. These three series illustrate the variety
of potential appearances of PGS, despite the use of the
same diagnostic criteria described by the WHO.
The findings on imaging are also variable. On computed
tomography (CT), the lesions can appear with large necrotic
areas and heterogenous contrast enhancement, similar to
that of GBMs, or as hyperdense lesions with well-defined
margins and homogenous enhancement, mimicking the
appearance of a meningioma [23, 24]. In a small case series
of five patients, Maiuri and colleagues [24] reported that
PGS resembling meningiomas on CT appeared similar to
meningiomas on gross pathology as well. However, this
correlation was not found in a subsequent report that
included 15 patients with PGS who received surgical
resection [21]. Of the 14 patients who were imaged by CT,
only 3 showed homogenous enhancement, similar to a
meningioma. Of 15 tumors that were excised, 13 showed
firm lesions with well demarcated margins, and two were
necrotic and infiltrating with ill defined borders. Detailed
descriptions of appearance on Magnetic Resonance Imag-
ing (MRI) are lacking, as the majority of large case series
were reported during the era when CT was the primary
method of imaging. Hence, reports of clinical correlation
with findings on MRI are also lacking. Recent case reports
show that findings on MRI are similar to those on CT, with
masses having heterogeneous enhancement and sharply
demarcated or irregular borders [4, 12, 18, 19, 25–30]. A
prominent and common feature of gliosarcomas seen on
MRI is marked peritumoral edema [18]. The difficulty in
establishing the diagnosis of PGS radiologically under-
scores the importance of establishing methods to make the
diagnosis histopathologically. The variability of radio-
graphic and pathologic presentations of gliosarcoma sug-
gests a potential need for an update of the WHO criteria
reflecting these potential clinical subtypes.
Despite its variable appearance, initial data have sup-
ported uniform aggressive treatment of PGS. Morantz and
Feigin as well as Parekh and colleagues [3, 21] warn that an
attempt to shell out PGS that resemble meningiomas will
likely result in persistence of tumor tissue with subsequent
recurrence. Currently, a reasonable approach to these tumors
is an attempt at gross total resection when possible. However
unlike GBM, there currently are no well controlled studies to
support the advantage of a gross total resection of PGS over
biopsy or subtotal resection followed by adjuvant therapy.
Metastasis
Extracranial metastases from cerebral gliomas, including
GBM, are very rare, while the propensity for gliosarcomas
to metastasize is well established. Even in the early days of
Feigin, several authors reported cases of metastatic foci
that contained admixtures of both gliomatous and sar-
comatous elements [2, 31, 32]. The presence of these
metastases was a large contribution to the premise that PGS
are a clinically separate entity from GBM and truly
biphasic in nature. Smith and colleages [33] in the largest
metastatic case series to date of seven cases of gliosarco-
mas, observed that in two cases, the metastatic foci were
composed solely of the sarcomatous component. Other
case reports followed with similar findings of sarcomatous
elements alone in metastases [25, 34–36]. These observa-
tions have generated the belief that the metastatic potential
of gliosarcoma is due to the sarcoma component and ulti-
mately reflects the strong propensity of sarcomatous neo-
plasms to disseminate hematogenously.
Most extracranial metastases of gliosarcoma are located
in the lung and liver, and there are reports of metastatic foci
in cervical lymph nodes, spleen, adrenal glands, kidneys,
oral mucosa, skin, bone marrow, skull, ribs, and spine [10,
31–40]. Intramedullary metastasis to the cervical spine has
also been observed [41]. There is a rare case of widespread
extracranial metastases with intravascular tumor emboli,
which is also consistent with the concept that gliosarcoma
metastasize via a hematogenous route [25].
Treatment
Treatment modalities described for gliosarcoma include
tumor resection, postoperative radiation therapy, and che-
motherapy with nitrosureas, misonidazole, dacarbazine,
mithramycin, ametophterin, thalidomide, temozolomide,
irinotecan, vincristine, cisplatin, or doxorubicin [18, 25,
42]. The majority of information on PGS therapy is derived
from published case series. Typically the described thera-
peutic modality is based on the prevailing treatment for
GBM that has demonstrated benefits in randomized trials. In
an early series of 24 cases by Morantz and colleagues, all 24
patients underwent surgical resection, 18 patients received
radiation therapy, and nine patients received chemotherapy
(mithramycin and ametophterin) [3]. The distribution of
316 J Neurooncol (2010) 96:313–320
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treatment modalities described in other larger case series
are similar with the majority of patients having undergone
surgical resection, a smaller portion having received ther-
apeutic radiation, and a few having received a wide range of
chemotherapeutic agents (Table 1) [12, 18, 20–22, 43].
The total dose delivered in radiotherapy ranged from 45
to 81 Gy in these reports. Because the role of radiation in
prolonging survival in GBM has been well established,
many of the previously mentioned authors implemented
postoperative radiotherapy for all patients with PGS,
despite lack of evidence for its benefit at the time [12, 18].
The small body of evidence in observational and cohort
studies available now supports the benefit of radiotherapy
in gliosarcoma. An interesting recent case report describes
recurrence of only the sarcomatous component of a PGS
after boron neutron capture therapy [26]. This case raises
the possibility of differential sensitivities to radiation of the
gliomatous and sarcomatous elements, although due to the
technique of boron neutron capture therapy, differential
accumulation of boron compounds in the glioma compo-
nent is an alternative explanation.
Although chemotherapy with temozolomide is now
standard of care for GBM, the precise role of chemother-
apy remains uncertain for PGS. Morantz and colleagues [3]
observed a modest increase in survival for PGS patients
when chemotherapy with mithramycin and ametophterin
(dose not reported) was added to postsurgical radiation
alone (36, 33 weeks respectively, no P value given). Other
authors did not offer chemotherapy to study participants,
citing its ill defined role [18, 43].
Currently, there is very little data regarding the response
of gliosarcoma to novel therapies that are being developed
and studied for malignant gliomas, such as immunotherapy
and cancer vaccine therapies. Most trials with malignant
glioma include gliosarcoma as a variant of GBM, and roles
of novel therapies in management of gliosarcoma becomes
difficult to parse out [44].
Prognosis
PGS has a poor prognosis with median survival in untreated
patients of 4 months [3]. For patients who underwent
treatment described in case series with 10 patients or more
(N = 154), the median survival was between 6.25 and
11.5 months per cohort (Table 1) [3, 12, 18, 20–22, 43].
Although a number of series suggested a slightly better
prognosis for PGS than for GBMs, four studies that included
a matched GBM control group failed to show a statistically
significant difference in survival (all four studies predate the
currently accepted radiotherapy with concurrent and adju-
vant temozolomide [45], as treatment for GBM, Table 2).
Meis and colleagues [22] found that median survival was T
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8.3 months for PGS patients compared to 9.6 months for
GBM patients (not statistically significant), Galanis and
colleagues [20] reported gliosarcoma patients had median
survival of 8.75 months and the matched controls with GBM
had median survival of 8.6 months (not statistically signif-
icant), Lutterbach and colleagues found median actuarial
survival to be 11.5 months for the group with gliosarcoma,
and 8.1 months for the control group with GBM (P = 0.36)
[18]. Miller and Perry [6] observed median survivals of
7.6 months for gliosarcoma group and 9.3 months for the
matched GBM controls (P = 0.33).
In a series of five gliosarcoma patients, Maiuri and
colleagues [24] noted an association of longer survival with
radiologic appearance similar to that of a meningioma and
prevalence of the sarcomatous element on histology.
Cervoni and Celli [26] also found in six patients that there
was increased survival in patients with PGS that resembled
meningiomas, and had dominance of the sarcomatous
component in comparison with those that did not (14 vs.
7 months, no P value given).
The benefit of radiation therapy on survival of patients
was described by Perry and colleagues [12], as radiation
treated patients had median survival of 10.6 months, com-
pared to 6.25 months in patients not treated with radiation
(P \ 0.025). The effect of chemotherapy has only been
commented on by Morantz and colleagues showing a mod-
est improvement in survival. Strong evidence supporting the
benefit of chemotherapy for PGS patients is lacking.
One peculiar case of a patient with prolonged survival has
been described by Winkler and colleagues [30]. A 61-year-
old patient with PGS experienced a recurrence 20 years after
initial diagnosis and treatment with repeated histological
confirmation. During the 2 years following recurrence, she
underwent multiple resections, radiotherapy, radiosurgery,
and intracavitary radioimmunotherapy, and ultimately pas-
sed away 22 years after initial diagnosis [3, 12, 43].
Future direction of pathogenesis and clinical
management
Current hypotheses on the pathogenesis of PGS include (1)
GBM promoting differentiation of local or circulating
mesenchymal stem cells into sarcoma, (2) sarcoma cells
converting local or circulating stem cells into differentiat-
ing into GBM, (3) one stem cell lineage ultimately giving
rise to both GBM and sarcoma, and (4) differentiated glial
cells of GBM undergo dedifferentiation and give rise to the
sarcoma. The concept of sarcoma induction by GBM is
consistent with the early hypothesis of Feigin based on
hyperplasia of vasculature seen in GBMs [2]. Alternatively,
primary CNS sarcomas have been reported, and the sar-
coma may induce malignant transformation in glial cells,
resulting in gliosarcoma. This hypothesis could be explored
by experiments co-culturing sarcomas and glial cells and
observing for possible malignant changes in glia. The last
two hypotheses, suggesting a monoclonal origin of both
parts of gliosarcoma, have been tested in experiments
identifying common genetic alterations in each cell type
[14–17]. However, in the case of PGS, there is the possi-
bility that transformations to glioma and sarcoma may
involve different genetic mutations. Considering the cur-
rent evidence to date, the monoclonal origin hypothesis
seems the most likely, or at least the most frequent method
of pathogenesis; however, further investigation is neces-
sary elucidate the exact mechanism of pathogenesis in
gliosarcoma.
Future clinical trials of malignant glioma would likely
benefit from considering gliosarcoma as a unique entity, in
order to limit confounding by the potential differential
characteristics between gliosarcoma and other gliomas in
prognostic markers as well as response to novel therapies.
However, comprehensive large prospective studies of gli-
osarcoma remain challenging due to the rarity of these
tumors.
Conclusions
PGS represents a clinically challenging group of tumors,
due to its rarity, poor prognosis, and the limited experience
in published literature. Many of its clinical and pathoge-
netic characteristics remain to be revealed, and there is
much room for future studies focusing on these biphasic
tumors. The current reported literature does provide a
number of distinguishing clinical and pathogenetic features
Table 2 Survival of gliosarcoma compared to glioblastoma multiforme
Study, year, ref. no. Number, GS/GBM Median survival
GS (months)
Median survival matched
GBM (months)
P
Meis, 1991 [22] 26/1453 (1.8%) 8.3 9.6 Non significant
Galanis, 1998 [20] 18/748 (2.4%) 8.75 8.6 Non significant
Lutterbach, 2001 [18] 12/420 (2.9%) 11.5 8.1 0.36
Miller, 2007 [6] 10/453 (2.2%) 7.6 9.3 0.33
318 J Neurooncol (2010) 96:313–320
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of PGS to suggest they are indeed separate entities from
GBMs. These differences include gliosarcomas’ temporal
lobe predilection, their potential to appear similar to a
meningioma grossly at operation, their increased metastatic
potential, and the infrequency of EGFR mutation. Evidence
for survival and efficacy of treatments is also limited due to
the difficulty of conducting prospective trials. However,
properly designed studies are necessary to optimize their
management by considering their differential clinical
behavior and pathogenesis from GBM. Although the pre-
cise etiology of PGS remains unknown, the interplay of
glioma and sarcoma genesis requires further investigation
to reveal potential targets for clinical applications.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Stroebe H (1895) Ueber Entstehung und Bau der Gehirnglioma.
Beitr Pathol Anat Allg Pathol 19:405–486
2. Feigin I, Gross SW (1954) Sarcoma arising in glioblastoma of the
brain. Am J Pathol 31:633–653
3. Morantz R, Feigin I, Ransohoff J (1976) Clinical and pathological
study of 24 cases of gliosarcoma. J Neurosurg 45:398–408
4. Cerda-Nicolas M, Kepes J (1993) Gliofibromas (including
malignant forms), and gliosarcomas: a comparative study and
review of literature. Acta Neuropathol 85:349–361
5. Louis D, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC,
Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO
classification of tumours of the central nervous system. Acta
Neuropathol 114:97–109
6. Miller C, Perry A (2006) Glioblastoma: morphologic and
molecular genetic diversity. Arch Pathol Lab Med 131:397–406
7. Feigin I, Allen LB, Lipkin L, Gross SW (1958) The endothelial
hyperplasia of cerebral blood vessels with brain tumors, and its
sarcomatous transformation. Cancer 2:264–277
8. McComb R, Jones TR, Pizzo SV, Bigner DD (1982) Immuno-
histochemical detection of factor VIII/von Willebrand factor in
hyperplastic endothelial cells in glioblastoma multiforme and
mixed glioma-sarcoma. J Neuropathol Exp Neurol 41:479–489
9. Slowik F, Jellinger K, Gaszo L, Fischer J (1985) Gliosarcomas:
histological, immunohistochemical, ultrastructural, and tissue
culture studies. Acta Neuropathol 67:201–210
10. Wharton S, Whittle IR, Collie DA, Bell HS, Ironside JW (2001)
Gliosarcoma with areas of primitive neuroepithelial differentia-
tion and extracranial metastasis. Clin Neuropathol 20:212–218
11. Grant J, Steart TV, Aguzzi A, Jones DB, Gallagher PJ (1989)
Gliosarcoma: an immunohistochemical study. Acta Neuropathol
79:305–309
12. Perry J, Ang LC, Bilbao JM, Muller PJ (1995) Clinicopathologic
features of primary and postirradiation cerebral gliosarcoma.
Cancer 75:2910–2918
13. Sreenan J, Prayson RA (1997) Gliosarcoma: a study of 13 tumors,
including p53 and CD34 immunohistochemistry. Arch Pathol Lab
Med 121:129–133
14. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME
(1995) Identical mutations of the p53 tumor suppressor gene in
the gliomatous and the sarcomatous components of gliosarcomas
suggest a common origin from glial cells. J Neuropathol Exp
Neurol 54:651–656
15. Reis R, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H
(2000) Genetic profile of gliosarcomas. Am J Pathol 156:425–
432
16. Actor B, Cobbers JM, Buschges R, Wolter M, Knobbe CB,
Lichter P, Reifenberger G, Weber RG (2002) Comprehensive
analysis of genomic alterations in gliosarcoma and its two tissue
components. Genes Chromosomes Cancer 34:416–427
17. Boerman R, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-
Klein J, Kirchof A, Raap AK, Scheithauer BW, Jenkins RB
(1996) The glilal and mesenchymal elements of gliosarcomas
share similar genetic alterations. J Neuropathol Exp Neurol
55:973–981
18. Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosar-
coma: a clinical study. Radiother Oncol 61:57–64
19. Machuca T, Prevedello DM, Pope LZ, Haratz SS, Araujo JC,
Torres LF (2004) Gliosarcoma: report of four cases with immu-
nohistochemical findings. Arq Neuropsiquiatr 62:608–612
20. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins
RB, Wang CH, O’Fallon JR, Farr G Jr (1998) Clinical outcome of
gliosarcoma compared with glioblastoma multiforme: north
central cancer treatment group results. J Neurosurg 89:425–430
21. Parekh H, O’Donovan DG, Sharma RR, Keogh AJ (1995) Pri-
mary cerebral gliosarcoma: report of 17 cases. Br J Neurosurg
9:171–178
22. Meis J, Martz KL, Nelson JS (1990) Mixed glioblastoma multi-
forme and sarcoma: a clinicopathologic study of 26 radiation
therapy oncology group cases. Cancer 67:2342–2349
23. Lee Y, Castillo M, Nauert C, Moser RP (1985) Computed
tomography of gliosarcoma. Am J Neuroradiol 4:527–531
24. Maiuri F, Stella L, Benvenuti D, Giamundo A, Pettinato G (1990)
Cerebral gliosarcomas: correlation of computed tomographic
findings, surgical aspect, pathological features, and prognosis.
Neurosurgery 26:261–267
25. Beaumont T, Kupsky WJ, Barger GR, Sloan AE (2007) Glio-
blastoma with multiple extracranial metastases: case report and
review of literature. J Neurooncol 83:39–46
26. Cervoni L, Celli P (1996) Cerebral gliosarcoma: prognostic fac-
tors. Neurosurg Rev 19:93–96
27. Deb P, Sharma MC, Chander B, Mahapatra AK, Sarkar C (2006)
Giant cell glioblastoma multiforme: report of a case with pro-
longed survival and transformation to gliosarcoma. Childs Nerv
Syst 22:314–319
28. Lieberman K, Fuller CE, Caruso RD, Schelper RL (2001) Post-
radiation gliosarcoma with osteosarcomatous components. Neu-
roradiology 43:555–558
29. Pakos E, Goussia AC, Zina VP, Pitouli EJ, Tsekeris PG (2005)
Multi-focal gliosarcoma: a case report and review of literature.
J Neurooncol 74:301–304
30. Winkler P, Buttner A, Tomezzoli A, Weis S (2000) Histologi-
cally repeatedly confirmed gliosarcoma with long survival:
review of literature and report of a case. Acta Neurochir 142:91–
95
31. Ehrenreich T, Devlin JF (1958) A complex of glioblastoma and
spindle-cell sarcoma with pulmonary metastases. Arch Pathol
66:536–549
32. Garret R (1958) Glioblastoma and fibrosarcoma of the brain with
extracranial metastases. Cancer 11:888–894
33. Smith D, Hardman JM, Earle KM (1969) Glioblastoma multi-
forme and fibrosarcoma with extracranial metastasis. Cancer
24:270–276
34. Gjedrum L, Bojsen-Moller M (1999) 61-year old male with brain
tumor and oral, lung, and palpebral masses. Brain Pathol 9:421–
422
J Neurooncol (2010) 96:313–320 319
123
35. Ojeda V, Sterrett GF (1984) Cerebral gliosarcoma, pulmonary
adenoid-cystic carcinoma, and pulmonary metastatic gliosar-
coma: report of an untreated case. Pathology 16:217–221
36. Weaver D, Vandenberg S, Park TS, Jane JA (1984) Selective
peripancreatic sarcoma metastases from primary gliosarcoma.
J Neurosurg 61:599–601
37. Cerame M, Guthikonda M, Kohli CM (1985) Extraneural
metastases in gliosarcoma: a case report and review of literature.
Neurosurgery 17:413–418
38. Matsuyama J, Mori T, Hori S, Nakano T, Yamada A (1989)
Gliosarcoma with multiple extracranial metastases. Case report.
Neurol Med Chir (Tokyo) 29:938–943
39. Slowik F, Balogh I (1980) Extracranial spreading of glioblastoma
multiforme. Zentralbl Neurochir 41:57–68
40. Yokoyama H, Ono H, Mori K, Kishikawa M, Kihara M (1985)
Extracranial metastasis of glioblastoma with sarcomatous com-
ponent. Surg Neurol 24:641–645
41. Witwer B, Salamat MS, Resnick DK (2000) Gliosarcoma meta-
static to the cervical spine cord: case report and review of the
literature. Surg Neurol 54:373–379
42. Rodriguez F, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy
P, Vlodavsky E, Schooley A, Landolfi J (2007) Gliosarcoma
arising in oligodendroglial tumors (‘‘oligosarcoma’’): a clinico-
pathologic study. Am J Surg Pathol 31:351–362
43. Sarkar C, Sharma MC, Sudha K, Gaikwad S, Varma A (1997) A
clinicopathological study of 29 cases of gliosarcoma with special
reference to two unique variants. Indian J Med Res 106:229–235
44. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R,
Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M,
Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT,
Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan
DA (2009) Phase II study of erlotinib plus temozolomide during
and after radiation therapy in patients with newly diagnosed glio-
blastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584
45. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ et al (2005) Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–
996
320 J Neurooncol (2010) 96:313–320
123
